Vera Therapeutics, Inc. (VERA)
Develops injectable drugs that calm overactive immune systems in kidney diseases.
$33.04-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+57.7%
The outlook
VERA is trading near its 52-week lows with a bearish lean from analysts overall. The stock sits below both its 50- and 200-day moving averages, though the average analyst price target sits roughly 148% above the current price, suggesting a wide gap between current valuation and where experts see potential value.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range38% of the way from its 52-week low to high
Price targetAvg target +148% vs current price
Analyst price target
~12-month · 14 analysts$81.79average target+147.5% vs now
Now $33.04
Low $43.00High $125.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.37B
52-wk high
$56.05
52-wk low
$19.07
50-day avg
$36.91
200-day avg
$38.90
Trailing P/E
—